ATE394481T1 - Transgentier-modell für die krankheit von alzheimer - Google Patents

Transgentier-modell für die krankheit von alzheimer

Info

Publication number
ATE394481T1
ATE394481T1 AT97934526T AT97934526T ATE394481T1 AT E394481 T1 ATE394481 T1 AT E394481T1 AT 97934526 T AT97934526 T AT 97934526T AT 97934526 T AT97934526 T AT 97934526T AT E394481 T1 ATE394481 T1 AT E394481T1
Authority
AT
Austria
Prior art keywords
app
transgenic
pathology
human
tau
Prior art date
Application number
AT97934526T
Other languages
English (en)
Inventor
Bernd Sommer
Matthias Staufenbiel
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9615569.2A external-priority patent/GB9615569D0/en
Priority claimed from GBGB9711262.7A external-priority patent/GB9711262D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE394481T1 publication Critical patent/ATE394481T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97934526T 1996-07-24 1997-07-23 Transgentier-modell für die krankheit von alzheimer ATE394481T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9615569.2A GB9615569D0 (en) 1996-07-24 1996-07-24 Improvements in or relating to organic compounds
GBGB9711262.7A GB9711262D0 (en) 1997-06-02 1997-06-02 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
ATE394481T1 true ATE394481T1 (de) 2008-05-15

Family

ID=26309753

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934526T ATE394481T1 (de) 1996-07-24 1997-07-23 Transgentier-modell für die krankheit von alzheimer

Country Status (8)

Country Link
EP (1) EP0920495B1 (de)
JP (2) JP2000515743A (de)
AT (1) ATE394481T1 (de)
AU (1) AU718473B2 (de)
DE (1) DE69738668D1 (de)
ES (1) ES2307300T3 (de)
PT (1) PT920495E (de)
WO (1) WO1998003644A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016951A1 (en) 1996-07-24 2001-08-23 Bernd Sommer Transgenic animal model for alzheimer disease
EP1063298A3 (de) * 1999-06-04 2001-03-28 Glaxo Group Limited Transgenes Tiermodell für die Krankheit von Alzheimer
GB0012056D0 (en) * 2000-05-18 2000-07-12 Consejo Superior Investigacion Model for neurodegenerative disease
NZ537688A (en) 2002-07-19 2007-01-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays for treating and/or attenuating Alzheimer's disease
SE0400707D0 (sv) 2004-03-22 2004-03-22 Bioarctic Neuroscience Ab Transgenic animal model
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
GB201204816D0 (en) 2012-03-19 2012-05-02 Brainco Biopharma S L Transgenic animal model of mood disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014200A1 (en) * 1992-01-07 1993-07-22 Tsi Corporation Transgenic animal models for alzheimer's disease
WO1994012627A1 (en) * 1992-11-25 1994-06-09 Cephalon, Inc. Transgenic animal model for alzheimer's disease
PT730643E (pt) * 1993-10-27 2001-06-29 Lilly Co Eli Animais transgenicos portadores do alelo de app com mutacao sueca

Also Published As

Publication number Publication date
AU3770797A (en) 1998-02-10
JP2000515743A (ja) 2000-11-28
PT920495E (pt) 2008-08-18
DE69738668D1 (de) 2008-06-19
EP0920495A1 (de) 1999-06-09
EP0920495B1 (de) 2008-05-07
JP2008054678A (ja) 2008-03-13
WO1998003644A1 (en) 1998-01-29
JP4302158B2 (ja) 2009-07-22
ES2307300T3 (es) 2008-11-16
AU718473B2 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
Orth et al. Stream habitat management
ATE276745T1 (de) Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter
Raber et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females
ATE315085T1 (de) Transgene mäuse mit veränderter apolipoprotein e- expression und testverfahren.
Pennacchio et al. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice
DE69133372D1 (de) Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
Luong et al. Genetic ablation of the CDP/Cux protein C terminus results in hair cycle defects and reduced male fertility
PL323109A1 (en) Genetic sequences and proteins associated with alzheimer disease and their application
CA2268812A1 (en) Method for producing transgenic animal models with modulated phenotype and animals produced therefrom
ATE394481T1 (de) Transgentier-modell für die krankheit von alzheimer
ATE541923T1 (de) Transgener c. elegans als modellorganismus für untersuchungen zur alzheimer'schen krankheit
Dancevic et al. The ADAMTS hyalectanase family: biological insights from diverse species
EP0981602A4 (de) Transgenes tier exprimierend nicht-natives wildtyp und familiäre alzheimer krankheit mutiertes presenilin-1 protein ohne ein hintergrundsniveau von nativen presenilin 1
ATE270328T1 (de) Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können
WO2002047477A3 (en) Transgenic mice containing huntingtin interacting protein 1 gene disruptions
Voipio et al. Role of cage material, working style and hearing sensitivity in perception of animal care noise
WO1998001549A3 (en) Genetic sequences and proteins related to alzheimer's disease, and uses therefor
DE60038966D1 (de) Transgenes tiermodel für neurodegenerative erkrankungen
FI951954A (fi) Transgeenisia eläimiä luuaineenvaihduntatautien malleina
ATE499832T1 (de) Transgenes tiermodel für neurodegenerative krankheiten
Koo et al. Identification of an enhancer region in the mouse ephA8 locus directing expression to the anterior region of the dorsal mesencephalon
KR101076837B1 (ko) 방사능 수치 측정 센서가 장착된 휴대용 기기에서의 사이버 생물 육성 장치 및 방법과 그 시스템
WO1998002036A3 (en) Animal model knock-out for a neuronal intermediate filament protein
CY1110304T1 (el) Διαγονιδιακο ζωο που εκφραζει μια πολυ-μεταλλαγμενη μορφη της πρεσενιλινης 1
FR2720894B1 (fr) Leurre odorant lumineux vibrant pour la pêche.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0920495

Country of ref document: EP

REN Ceased due to non-payment of the annual fee